Inhibition of human recombinant T‐type calcium channels by phytocannabinoids in vitro.

Autor: Mirlohi, Somayeh¹ (AUTHOR), Bladen, Chris¹ (AUTHOR), Santiago, Marina J.¹ (AUTHOR), Arnold, Jonathon C.^2,3 (AUTHOR), McGregor, Iain² (AUTHOR), Connor, Mark¹ (AUTHOR) mark.connor@mq.edu.au

Publikováno v: British Journal of Pharmacology. Aug2022, Vol. 179 Issue 15, p4031-4043. 13p. 2 Charts, 6 Graphs.

Modulation of Recombinant Human T-Type Calcium Channels by Δ⁹-Tetrahydrocannabinolic Acid In Vitro.

Autor: Mirlohi, Somayeh, Bladen, Chris, Santiago, Marina, Connor, Mark

Publikováno v: Cannabis & Cannabinoid Research; Feb2022, Vol. 7 Issue 1, p34-45, 12p

Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca V 3) Inhibitors.

Autor: Kevin RC; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Pharmacy, The University of Sydney, NSW 2006, Australia., Mirlohi S; Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia., Manning JJ; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand., Boyd R; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Chemistry, The University of Sydney, NSW 2006, Australia., Cairns EA; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Psychology, The University of Sydney, NSW 2006, Australia., Ametovski A; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Chemistry, The University of Sydney, NSW 2006, Australia., Lai F; School of Pharmacy, The University of Sydney, NSW 2006, Australia., Luo JL; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Psychology, The University of Sydney, NSW 2006, Australia., Jorgensen W; School of Chemistry, The University of Sydney, NSW 2006, Australia., Ellison R; Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States., Gerona RR; Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States., Hibbs DE; School of Pharmacy, The University of Sydney, NSW 2006, Australia., McGregor IS; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Psychology, The University of Sydney, NSW 2006, Australia., Glass M; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand., Connor M; Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia., Bladen C; Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.; Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Zamponi GW; Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Banister SD; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.; School of Chemistry, The University of Sydney, NSW 2006, Australia.

Publikováno v: ACS chemical neuroscience [ACS Chem Neurosci] 2022 May 04; Vol. 13 (9), pp. 1395-1409. Date of Electronic Publication: 2022 Apr 20.